Earendil Labs Secures $787 Million to Scale AI-Driven Biologics Pipeline and Partnerships

New updates have been reported about Earendil Labs.

Earendil Labs has raised $787 million in new financing to expand its AI-centric biologics platform, marking one of the largest recent private rounds in AI-enabled drug discovery. The capital, backed by investors including Dimension Capital, DST Global, Sanofi, and the Biotech Development Fund created by Hillhouse and Pfizer, positions the company to operate at materially greater R&D scale and to advance multiple assets toward clinical inflection points.

Management plans to deploy the funding to grow interdisciplinary scientific, engineering, and translational teams and to accelerate a portfolio exceeding 40 biologic programs, anchored by HXN-1001, a half-life extended anti-TL1A antibody now ready for Phase 2 development. Earendil Labs expects multiple IND filings across 2026 and 2027, leveraging an AI-native platform that integrates machine learning across the full biologics life cycle, from design through optimization and preclinical progression.

CEO and founder Jian Peng, PhD, emphasized that AI functions as the company’s core production engine rather than a peripheral research tool, enabling systematic generation of first-in-class and best-in-class therapeutic candidates. Co-founder and Co-CEO Zhenping Zhu, MD, PhD, highlighted that the scaled capital base will support both internal pipeline advancement and external collaborations aimed at diseases with limited treatment options, particularly in autoimmune and inflammatory conditions.

Earendil’s strategy is reinforced by a deepening relationship with Sanofi, which includes a worldwide exclusive license signed in 2025 for next-generation bispecific antibodies HXN-1002 and HXN-1003 targeting autoimmune and inflammatory bowel diseases. A subsequent broader strategic collaboration gives Sanofi access to Earendil’s AI discovery engine across multiple autoimmune and inflammatory programs, providing external validation of the platform’s productivity and potential for global reach.

Lead investor Dimension Capital cited Earendil’s ability to repeatedly generate and advance high-quality biologics as evidence that AI-driven R&D can scale beyond proof-of-concept. For executives and investors, the transaction materially strengthens Earendil Labs’ balance sheet, extends its runway for clinical and partnership milestones, and positions the company as a key private contender in AI-enabled biologics, with upside tied to successful Phase 2 readouts, IND progression, and expansion of high-value strategic alliances.